Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Not taking gastroprotective drugs prescribed with anti-inflammatory medicines

16.04.2012
Increases risk of upper GI complications

To relieve pain, arthritis sufferers are prescribed medications that may include non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors, both of which can irritate the digestive tract.

At times additional drugs are co-prescribed with NSAIDs or COX-2 inhibitors to prevent adverse gastrointestinal (GI) effects. Now a new study available today in the American College of Rheumatology journal, Arthritis & Rheumatism, reveals that decreasing gastroprotective agent (GPA) adherence among users of COX-2 inhibitors is linked to an increased risk of such upper GI complications.

Current clinical guidelines recommend that GPAs, such as proton pump inhibitors (PPIs) or misoprostol, be prescribed to patients taking NSAIDs and COX-2 inhibitors—also known as COX-2 blockers—who are at high risk of upper GI events. Previous research shows that in NSAID users who fail to adhere to the GPA regimen, the protective effect of GPA drugs is diminished. However, limited evidence is available regarding the effect of adherence to a gastroprotective drug regimen with COX-2 blocker use, and is the focus of the current investigation led by Dr. Vera Valkhoff with Erasmus University Medical Center in the Netherlands.

Dr. Valkhoff and colleagues analyzed data from population-based primary care registries in the United Kingdom, the Netherlands, and Italy between 1996 and 2008. The study group included 14,416 patients 50 years of age or older who were prescribed COX-2 inhibitors and GPAs. Researchers calculated GPA adherence as the proportion of the COX-2 blocker treatment days covered by a GPA prescription. Cases were part of the COX-2 blocker plus GPA group who had an upper GI complication (GI bleeding or symptomatic ulcer) which included 16,442 episodes.

Researchers noted that of the COX-2 blockers prescribed 43% of participants used celecoxib (Celebrex), 41% rofecoxib (Vioxx),1 and 15% etoricoxib (Arcoxia),2 with most patients using these drugs for less than 30 days. During the study 74 patients had an upper GI event, resulting in an incidence rate of 11.9 per 1,000 COX-2 inhibitor user years. Results showed that the risk of upper GI complication was higher in low GPA adherers (GPA was taken on average one out of five days of COX-2 blocker use, or less) compared to full adherers (GPA was taken four out of five days of COX-2 inhibitor use, or more).

Further analysis found that for every 10% decrease in GPA adherence, there was a 9% increase in the risk of gastrointestinal complications. "Our findings show that with every three day reduction of GPA coverage per 30 days of COX-2 inhibitor use, the risk of upper GI events increases 9%," concludes Dr. Valkhoff. "This study confirms the benefits of GPA adherence in reducing risk of upper GI complications from use of COX-2 blockers." The authors point out that GPA adherence is important in reducing risk of upper GI events with COX-2 blockers, and non-adherence is a modifiable risk factor while conventional risk factors such as a prior GI event or use of anticoagulant therapy are not.

1 In May 1999 the Federal Drug Administration (FDA) approved rofecoxib (Vioxx) for treatment of osteoarthritis (OA) and later approved to relieve symptoms of rheumatoid arthritis (RA). In September 2004 Merck & Co., Inc. withdrew the drug from U.S. and worldwide markets due to increased risk of heart attack and stroke in patients using rofecoxib according to the FDA postmarket drug safety information.

2 Etoricoxib (Arcoxia) is not available in the U.S.

This study is published in Arthritis & Rheumatism. Media wishing to receive a PDF of this article may contact healthnews@wiley.com

Full citation: "Adherence to Gastroprotection During Cyclooxygenase-2 Inhibitor Use and the Risk of Upper Gastrointestinal Events: A Population-based Study." Vera E Valkhoff, Eva M van Soest, Giampiero Mazzaglia, Mariam Molokhia, Rene Schade, Gianluca Trifiro, Jay L Goldstein, Sonia Hernandez-Diaz, Ernst J Kuipers, Miriam C J M Sturkenboom. Arthritis & Rheumatism; Published Online: April 16, 2012 (DOI: 10.1002/art.34433).

Author Contacts: To arrange an interview with Dr. Vera Valkhoff or Dr. Miriam Sturkenboom, please contact David Drexhage with Erasmus MC at d.drexhage@erasmusmc.nl.

About the Journal:

Arthritis & Rheumatism is an official journal of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP), a division of the College, and covers all aspects of inflammatory disease. The American College of Rheumatology (http://www.rheumatology.org) is the professional organization who share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley-Blackwell on behalf of the ACR. For more information, please visit http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.

About Wiley-Blackwell:

Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit http://www.wileyblackwell.com or our new online platform, Wiley Online Library (http://www.wileyonlinelibrary.com), one of the world's most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.

Dawn Peters | EurekAlert!
Further information:
http://www.wiley.com

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>